Ginkgo Pharma

Chinese, clinical-stage biopharma developing targeted Hepatitis C virus NS3 protein inhibitors

placeSuzhou, Jiangsu, China calendar_todayFounded 2009 language ginkgopharma.com

Innovation

6 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace dormant. Cited 36 times.

YearFilings
20132
20141
20151
20162
20182
20192

Investor mix

5 investors on record.

Investor typeCountShare
Venture capital120%
Private equity360%
Other / undisclosed120%
Coming soon